
Claims


1. A pharmaceutical composition comprising a compound of formula (I):



(I)

or a pharmaceutically acceptable salt thereof, and one or more therapeutic agents selected from tretinoin, cytarabine, pinometostat, vorinostat, ricolinostat, entinostat, decitabine, azacitidine, quizartinib, ABT-737, venetoclax, nutlin-3A, dasatinib, JQ1, and pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients.


2. Use of a combination comprising a compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof, and one or more therapeutic agents selected from tretinoin, cytarabine, pinometostat, vorinostat, ricolinostat, entinostat, decitabine, azacitidine, quizartinib, ABT-737, venetoclax, nutlin-3A, dasatinib, JQ1, and pharmaceutically acceptable salts thereof, for the preparation of a medicament for the treatment of a hyperproliferative disorder.

3. Use of a compound of formula (I)




(I)

or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of a hyperproliferative disorder, wherein the compound of formula (I) is to be administered with one or more therapeutic agents selected from tretinoin, cytarabine, pinometostat, vorinostat, ricolinostat, entinostat, decitabine, azacitidine, quizartinib,

ABT-737, venetoclax, nutlin 3A, dasatinib, JQ1, and pharmaceutically acceptable salts thereof.


4. Use of one or more therapeutic agents selected from tretinoin, cytarabine, pinometostat, vorinostat, ricolinostat, entinostat, decitabine, azacitidine, quizartinib, ABT-737, venetoclax, nutlin 3A, dasatinib, JQ1, and pharmaceutically acceptable salts thereof, for the preparation of a medicament for the treatment of a hyperproliferative disorder, wherein the one or more therapeutic agents is to be administered with a compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof.


5. Use of a combination comprising a compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof, and one or more therapeutic agents selected from tretinoin, cytarabine, pinometostat, vorinostat, ricolinostat, entinostat, decitabine, azacitidine, quizartinib, ABT-737, venetoclax, nutlin 3A, dasatinib, JQ1, and pharmaceutically acceptable salts thereof, for the preparation of a medicament for the treatment of a hematological malignancy.


6. Use of a compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of a hematological malignancy, wherein the compound of formula (I) is to be administered with one or more therapeutic agents selected from tretinoin, cytarabine, pinometostat, vorinostat, ricolinostat, entinostat, decitabine, azacitidine, quizartinib, ABT-737, venetoclax, nutlin 3A, dasatinib, JQ1, and pharmaceutically acceptable salts thereof.

7. Use of one or more therapeutic agents selected from tretinoin, cytarabine, pinometostat, vorinostat, ricolinostat, entinostat, decitabine, azacitidine, quizartinib, ABT-737, venetoclax, nutlin 3A, dasatinib, JQ1, and pharmaceutically acceptable salts thereof, for the preparation of a medicament for the treatment of a hematological malignancy, wherein the one or more therapeutic agents is to be administered with a compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof.

8. The use according to any one of claims 2 to 7, wherein the therapeutic agent is cytarabine or a pharmaceutically acceptable salt thereof.

9. The use according to any one of claims 2 to 7, wherein the therapeutic agent is decitabine or a pharmaceutically acceptable salt thereof.

10. The use according to any one of claims 2 to 7, wherein the therapeutic agent is azacitidine or a pharmaceutically acceptable salt thereof.

11. The use according to any one of claims 2 to 7, wherein the therapeutic agent is venetoclax or a pharmaceutically acceptable salt thereof.

12. The use according to any one of claims 2 to 11, wherein the dihydrochloride salt of a compound of formula (I) is used.

13. The use according to any one of claims 2 to 12, wherein the medicament is to be administered as a simultaneous regimen or a sequential regimen.

14. The use of any one of claims 5 to 13, wherein the hematological malignancy is a myeloid hematological malignancy.

15. The use of claim 14, wherein the myeloid hematological malignancy is acute myeloid leukemia.

16. The use of claim 14, wherein the myeloid hematological malignancy is chronic myelogenous leukemia, myelodysplastic syndrome, or a myeloproliferative disease.

17. The use of claim 14, wherein the myeloid hematological malignancy is a myeloproliferative disease which is selected from the group consisting of myelofibrosis, acute biphenotypic leukemia, polycythemia vera, essential thrombocytosis, and chronic eosinophilic leukemia/hypereosinophilic syndrome.

18. The use of any one of claims 5 to 13, wherein the hematological malignancy is a lymphoid hematological malignancy.

19. The use of claim 18, wherein the lymphoid hematological malignancy is acute lymphoblastic leukemia.